Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer

被引:0
|
作者
Nathalie Harder
Maria Athelogou
Harald Hessel
Nicolas Brieu
Mehmet Yigitsoy
Johannes Zimmermann
Martin Baatz
Alexander Buchner
Christian G. Stief
Thomas Kirchner
Gerd Binnig
Günter Schmidt
Ralf Huss
机构
[1] Definiens AG,Department of Urology
[2] Institute for Pathology,undefined
[3] Ludwig-Maximilians-University,undefined
[4] Ludwig-Maximilians-University,undefined
[5] Carl Zeiss Meditec AG,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Tissue Phenomics is the discipline of mining tissue images to identify patterns that are related to clinical outcome providing potential prognostic and predictive value. This involves the discovery process from assay development, image analysis, and data mining to the final interpretation and validation of the findings. Importantly, this process is not linear but allows backward steps and optimization loops over multiple sub-processes. We provide a detailed description of the Tissue Phenomics methodology while exemplifying each step on the application of prostate cancer recurrence prediction. In particular, we automatically identified tissue-based biomarkers having significant prognostic value for low- and intermediate-risk prostate cancer patients (Gleason scores 6–7b) after radical prostatectomy. We found that promising phenes were related to CD8(+) and CD68(+) cells in the microenvironment of cancerous glands in combination with the local micro-vascularization. Recurrence prediction based on the selected phenes yielded accuracies up to 83% thereby clearly outperforming prediction based on the Gleason score. Moreover, we compared different machine learning algorithms to combine the most relevant phenes resulting in increased accuracies of 88% for tumor progression prediction. These findings will be of potential use for future prognostic tests for prostate cancer patients and provide a proof-of-principle of the Tissue Phenomics approach.
引用
收藏
相关论文
共 50 条
  • [21] The role of endogenous testosterone in relationship with low- and intermediate-risk prostate cancer: a systematic review
    Porcaro, Antonio Benito
    Serafin, Emanuele
    Brusa, Davide
    Costantino, Sonia
    Brancelli, Claudio
    Cerruto, Maria Angela
    Antonelli, Alessandro
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 569 - 574
  • [22] Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
    Kim, Hun Jung
    Phak, Jeong Hoon
    Kim, Woo Chul
    RADIATION ONCOLOGY JOURNAL, 2016, 34 (04): : 260 - 264
  • [23] Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
    Jeong, Bae-Kwon
    Jeong, Hojin
    Ha, In Bong
    Choi, Hoon Sik
    Kam, Sung Chul
    Hwa, Jeong Seok
    Hyun, Jae Seog
    Chung, Ky Hyun
    Choi, See Min
    Kang, Ki Mun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (06) : 710 - 715
  • [24] Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review
    Rodrigues, George
    Yao, Xiaomei
    Loblaw, D. Andrew
    Brundage, Michael
    Chin, Joseph L.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2013, 7 (11-12): : 463 - 470
  • [25] No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
    Cyll, Karolina
    Loffeler, Sven
    Carlsen, Birgitte
    Skogstad, Karin
    Plathan, May Lisbeth
    Landquist, Martin
    Haug, Erik Skaaheim
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [26] Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease
    Walser, Eric
    Nance, Anne
    Ynalvez, Leslie
    Yong, Shan
    Aoughsten, Jacqueline S.
    Eyzaguirre, Eduardo J.
    Williams, Stephen B.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 30 (03) : 401 - 409
  • [27] A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer
    Taussky, Daniel
    Ouellet, Veronique
    Delouya, Guila
    Saad, Fred
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (7-8): : 246 - 250
  • [28] Controversies in Radioiodine Treatment of Low- and Intermediate-risk Thyroid Cancer
    Eilsberger, F.
    Verburg, F. A.
    CLINICAL ONCOLOGY, 2021, 33 (02) : 68 - 74
  • [29] A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer
    Kato, Takuma
    Tohi, Yoichiro
    Honda, Tomoko
    Matsuda, Iori
    Osaki, Yu
    Naito, Hirohito
    Matsuoka, Yuki
    Okazoe, Homare
    Taoka, Rikiya
    Tsunemori, Hiroyuki
    Ueda, Nobufumi
    Sugimoto, Mikio
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (03) : 289 - 297
  • [30] No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
    Karolina Cyll
    Sven Löffeler
    Birgitte Carlsen
    Karin Skogstad
    May Lisbeth Plathan
    Martin Landquist
    Erik Skaaheim Haug
    Scientific Reports, 12